First author (pub. yr.) | Study period | Location | Â | N | Â | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Recruitment method | Recruitment site | Definition of HCV clearance | Quality rating | Participants | Clearers | Proportion of clearance events | 95Â % CI | |||||
Bottieau (2010) [62] | 2001–2009 | Belgium | Consecutive sampling | Clinical setting | ≥1 RNA- within 6 months | Moderate | 65 | 7 | 10.8 | 3.2 | - | 18.3 |
Dietz (2012) [63] | Not reported | Germany | Not reported | Not reported | Methods not reported | Low | 47 | 4 | 8.5 | 0.5 | - | 16.5 |
Fierer(2014) [64] | Not reported | United States | Not reported | Not reported | ≥1 RNA- within 3 months | Moderate | 41 | 5 | 12.2 | 2.2 | - | 22.2 |
Fletcher (2003) [65] | 2002–2003 | United Kingdom | Not reported | Clinical setting | ≥1 RNA- result | Moderate | 16 | 6 | 37.5 | 13.8 | - | 61.2 |
Gilleece (2005) [66] | 1997–2003 | United Kingdom | Not reported | Clinical setting | >1 RNA- result within 3 months | Moderate | 50 | 12 | 24.0 | 12.2 | - | 35.8 |
Grebely (2014) [29] | 1985–2010 | Multiple locations | Not reported | Clinical, community-based, and correctional settings | 2 consecutive RNA- results separated by at least 1 month | Moderate | 11 | 0 | — | — | ||
Martin (2013) [67] | 2004–2014 | United Kingdom | Consecutive sampling | Clinical setting | 2 RNA- results after 6 months | High | 145 | 31 | 21.4 | 14.7 | - | 28.1 |
Piroth (2010) [68] | 2008–2009 | France | Consecutive sampling | Clinical setting | ≥1 RNA- | High | 53 | 8 | 15.1 | 5.5 | - | 24.7 |
Sasadeusz (2011) [69] | 2003–2007 | Not reported | Consecutive sampling | Clinical setting | 2 consecutive RNA- results separated by at least 3 months | Low | 61 | 9 | 14.8 | 5.9 | - | 23.7 |
Thomson (2011) [70] | 2005–2009 | United Kingdom | Not reported | Clinical setting | 2 consecutive RNA- results separated by at least 3 months | Moderate | 99 | 14 | 14.1 | 7.3 | - | 21.0 |